Crispr Therapeutics AG (CRSP) Insider Trading
- $27,833,805.86
- $313,185,058.53
- April 15, 2024
- Samarth Kulkarni
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
April 15, 2024 | CEO | 19,582 | $59.91 | Sell | $1,173,157.62 | |
March 15, 2024 | CFO | 3,524 | $72.69 | Sell | $256,159.56 | |
March 15, 2024 | CEO | 20,000 | $72.48 | Sell | $1,449,600.00 | |
March 11, 2024 | General Counsel | 2,801 | $78.26 | Sell | $219,206.26 | |
March 11, 2024 | CEO | 9,802 | $78.26 | Sell | $767,104.52 | |
Feb. 20, 2024 | CEO | 6,370 | $79.67 | Sell | $507,497.90 | |
Feb. 20, 2024 | General Counsel | 1,913 | $79.67 | Sell | $152,408.71 | |
Feb. 15, 2024 | CEO | 20,000 | $80.36 | Sell | $1,607,200.00 | |
Jan. 29, 2024 | CEO | 50,000 | $60.51 | Sell | $3,025,500.00 | |
Jan. 16, 2024 | CEO | 20,000 | $62.50 | Sell | $1,250,000.00 | |
May 30, 2023 | CEO | 25,000 | $64.88 | Sell | $1,622,000.00 | |
April 25, 2023 | CEO | 25,000 | $50.67 | Sell | $1,266,750.00 | |
March 29, 2023 | CEO | 25,000 | $44.46 | Sell | $1,111,500.00 | |
Feb. 27, 2023 | CEO | 25,000 | $48.25 | Sell | $1,206,250.00 | |
Jan. 27, 2023 | CEO | 25,000 | $51.47 | Sell | $1,286,750.00 | |
Dec. 28, 2022 | CEO | 25,000 | $40.93 | Sell | $1,023,250.00 | |
Nov. 28, 2022 | CEO | 25,000 | $54.03 | Sell | $1,350,750.00 | |
Oct. 26, 2022 | CEO | 25,000 | $54.81 | Sell | $1,370,250.00 | |
Sept. 28, 2022 | CEO | 25,000 | $64.61 | Sell | $1,615,250.00 | |
Aug. 29, 2022 | CEO | 25,000 | $66.84 | Sell | $1,671,000.00 | |
July 27, 2022 | CEO | 25,000 | $75.91 | Sell | $1,897,750.00 | |
June 29, 2022 | CEO | 25,000 | $61.59 | Sell | $1,539,750.00 | |
Aug. 6, 2021 | CFO | 25,000 | $138.52 | Sell | $3,463,000.00 | |
Aug. 4, 2021 | CEO | 1,500 | $125.02 | Sell | $187,530.00 | |
July 19, 2021 | Director | 10,000 | $126.43 | Sell | $1,264,300.00 | |
June 30, 2021 | President | 25,000 | $165.00 | Sell | $4,125,000.00 | |
June 28, 2021 | Director | 20,375 | $152.48 | Sell | $3,106,780.00 | |
June 21, 2021 | President | 25,000 | $128.62 | Sell | $3,215,500.00 | |
June 15, 2021 | CEO | 30,000 | $126.43 | Sell | $3,792,900.00 | |
June 11, 2021 | Director | 10,000 | $126.61 | Sell | $1,266,100.00 | |
March 22, 2021 | Director | 30,374 | $132.37 | Sell | $4,020,606.38 | |
Jan. 19, 2021 | General Counsel | 27,500 | $204.94 | Sell | $5,635,850.00 | |
Jan. 15, 2021 | COO | 25,000 | $215.20 | Sell | $5,380,000.00 | |
Jan. 15, 2021 | CEO | 20,000 | $213.67 | Sell | $4,273,400.00 | |
Dec. 21, 2020 | VP | 23,551 | $149.23 | Sell | $3,514,515.73 | |
Dec. 16, 2020 | Director | 7,648 | $148.95 | Sell | $1,139,169.60 | |
Dec. 10, 2020 | CEO | 20,000 | $142.29 | Sell | $2,845,800.00 | |
Dec. 10, 2020 | Director | 33,000 | $143.35 | Sell | $4,730,550.00 | |
Dec. 7, 2020 | Director | 171,004 | $154.53 | Sell | $26,425,248.12 | |
Nov. 30, 2020 | President | 100,000 | $125.00 | Sell | $12,500,000.00 | |
Sept. 18, 2020 | Director | 3,035 | $86.87 | Sell | $263,650.45 | |
Sept. 16, 2020 | Director | 8,965 | $86.98 | Sell | $779,775.70 | |
Sept. 14, 2020 | Director | 1,155 | $84.89 | Sell | $98,047.95 | |
Sept. 10, 2020 | Director | 22,845 | $85.36 | Sell | $1,950,049.20 | |
Sept. 1, 2020 | President | 25,000 | $92.62 | Sell | $2,315,500.00 | |
Sept. 1, 2020 | CFO | 12,000 | $92.26 | Sell | $1,107,120.00 | |
Sept. 1, 2020 | Director | 60,000 | $92.51 | Sell | $5,550,600.00 | |
July 7, 2020 | President | 25,000 | $90.00 | Sell | $2,250,000.00 | |
July 6, 2020 | Director | 20,000 | $82.39 | Sell | $1,647,800.00 | |
June 24, 2020 | COO | 65,088 | $75.93 | Sell | $4,942,131.84 |
Insiders are both buying and selling Crispr Therapeutics AG stock.
The insider traders at Crispr Therapeutics AG are: Samarth Kulkarni, Rodger Novak, Kurt Von Emster, Bradley J Phd Bolzon, Corp /De/ Celgene, Tyler Dylan-Hyde, Pablo J Cagnoni, Lawrence Otto Klein, Thomas Woiwode, Vertex Pharmaceuticals (Europe, Michael John Tomsicek, James R Kasinger, Raju Prasad, Bradley J. Phd Bolzon, James R. Kasinger, Aktiengesellschaft Bayer, Simeon George, Tony W Ho, Tony W. Ho, and Versant Venture Capital V, L.P
The most active insider trader at Crispr Therapeutics AG is Samarth Kulkarni with 31 trades.
Kurt Von Emster has sold the most Crispr Therapeutics AG stock with a total value of $68,130,025.01.
Aktiengesellschaft Bayer has bought the most Crispr Therapeutics AG stock with a total value of $23,999,976.00.
The most recent insider trade for Crispr Therapeutics AG was on April 15, 2024.
The single biggest insider buy for Crispr Therapeutics AG was from Aktiengesellschaft Bayer with a total value of $11,999,988.00 on Jan. 5, 2018.
The single biggest insider sell for Crispr Therapeutics AG was from Kurt Von Emster with a total value of $35,353,500.00 on May 14, 2018.